Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
2.
J Am Coll Nutr ; 26(5): 405-11, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17914127

ABSTRACT

OBJECTIVE: This trial evaluated the effect of antioxidant supplementation on the urinary excretion of 11-dehydro TXB(2)/2,3 dinor 6 keto PGF(1alpha) ratio, a marker of the pathogenesis of thrombosis and arteriosclerosis. METHODS: This study was a randomised, double-blind, placebo-controlled trial involving 186 presumably healthy volunteers. One hundred received a multi-antioxidant supplementation and 86 a placebo for two years. Blood zinc, selenium, beta-carotene, vitamin C and E and urinary excretion of 11-dehydro TXB(2) and 2,3 dinor 6 keto PGF(1alpha) were measured. RESULTS: Baseline subject characteristics did not differ between the two groups. Blood zinc, selenium, and beta-carotene concentrations significantly increased between baseline and two years in the multi-antioxidant supplementation group supporting subject compliance (p < 0.05). At two years, the median urinary 11-dehydro TXB(2)/2,3 dinor 6 keto PGF(1alpha) ratio was significantly lower in the multi-antioxidant supplementation group (3.4 versus 2.78, p = 0.015). Serum selenium concentration was the only antioxidant studied that was significantly related to the urinary 11-dehydro TXB(2)/2,3 dinor 6 keto PGF(1alpha) ratio. CONCLUSIONS: These results support the hypothesis that a low-dose multi-antioxidant supplementation may contributes to a reduction in platelet activation which is beneficial for cardiovascular function.


Subject(s)
Antioxidants/metabolism , Prostaglandins I/urine , Thromboxanes/urine , Trace Elements/metabolism , Vitamins/metabolism , 6-Ketoprostaglandin F1 alpha/analogs & derivatives , 6-Ketoprostaglandin F1 alpha/urine , Antioxidants/administration & dosage , Arteriosclerosis/blood , Arteriosclerosis/prevention & control , Biomarkers/urine , Dietary Supplements , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Middle Aged , Patient Compliance , Platelet Activation/drug effects , Selenium/administration & dosage , Selenium/blood , Thrombosis/blood , Thrombosis/prevention & control , Thromboxane B2/analogs & derivatives , Thromboxane B2/urine , Trace Elements/administration & dosage , Vitamins/administration & dosage , Zinc/administration & dosage , Zinc/blood , beta Carotene/administration & dosage , beta Carotene/blood
4.
J Nutr Biochem ; 14(11): 626-32, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14629893

ABSTRACT

In this study we investigated the role of a mixture of n-6/n-3 essential fatty acids, in the cyclosporine model nephrotoxicity. Administration of cyclosporine in rats decreased creatinine clearance and provoked body weight loss, but it did not induce proteinuria and did not alter the urine volume. These changes were associated with decreased urinary ratios of prostaglandin E/thromboxane B and prostaglandin I/thromboxane B excretions. Light microscopic sections showed that 100% of the animals were affected by histological tubular lesions on their kidneys. Administration of cyclosporine to animals fed for 3 months on standard chow containing a mixture of n - 6/n - 3 essential fatty acids, restored creatinine clearance, augmented urine volume and prevented body weight loss. The improvement of renal function was accompanied by increased urinary ratios of prostaglandin E/thromboxane B and prostaglandin I/thromboxane B excretions. Light microscopic sections showed that only 40% of the animals demonstrated histological tubular lesions, of minor importance, to their kidneys. Our results suggest that the metabolites of arachidonic acid can play important role in the development of cyclosporine-nephrotoxicity because they increase the levels of thromboxane A and that the enhanced synthesis of prostaglandins (E) and (I) induced by a mixture of n - 6/n - 3 essential fatty acids, could play a beneficial role in the prevention of this renal dysfunction.


Subject(s)
Cyclosporine/toxicity , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-6/administration & dosage , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , 6-Ketoprostaglandin F1 alpha/urine , Animals , Arachidonic Acid/metabolism , Creatinine/metabolism , Dinoprostone/urine , Female , Kidney/pathology , Kidney/physiopathology , Kidney Diseases/physiopathology , Prostaglandins I/urine , Rats , Rats, Wistar , Thromboxane B2/urine , Urine , Weight Loss
5.
J Nutr Biochem ; 14(8): 480-6, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12948879

ABSTRACT

In this study we investigated the role of a mixture of n-6/n-3 essential fatty acids, in the cyclosporine model nephrotoxicity. Administration of cyclosporine in rats decreased creatinine clearance and provoked body weight loss, but it did not induce proteinuria and did not alter the urine volume. These changes were associated with decreased urinary ratios of prostaglandin E/thromboxane B and prostaglandin I/thromboxane B excretions. Light microscopic sections showed that 100% of the animals were affected by histological tubular lesions on their kidneys. Administration of cyclosporine to animals fed for 3 months on standard chow containing a mixture of n - 6/n - 3 essential fatty acids, restored creatinine clearance, augmented urine volume and prevented body weight loss. The improvement of renal function was accompanied by increased urinary ratios of prostaglandin E/thromboxane B and prostaglandin I/thromboxane B excretions. Light microscopic sections showed that only 40% of the animals demonstrated histological tubular lesions, of minor importance, to their kidneys. Our results suggest that the metabolites of arachidonic acid can play important role in the development of cyclosporine-nephrotoxicity because they increase the levels of thromboxane A and that the enchanced synthesis of prostaglandins (E) and (I) induced by a mixture of n - 6/n - 3 essential fatty acids, could play a beneficial role in the prevention of this renal dysfunction.


Subject(s)
Cyclosporine/toxicity , Dietary Fats, Unsaturated/administration & dosage , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-6/administration & dosage , Kidney Diseases/prevention & control , 6-Ketoprostaglandin F1 alpha/urine , Animals , Dinoprostone/urine , Female , Kidney/physiopathology , Kidney Diseases/chemically induced , Kidney Diseases/physiopathology , Prostaglandins I/urine , Proteinuria , Rats , Rats, Wistar , Thromboxane B2/urine , Weight Loss
SELECTION OF CITATIONS
SEARCH DETAIL
...